Luminex (NASDAQ:LMNX) is scheduled to be posting its quarterly earnings results after the market closes on Monday, February 12th. Analysts expect Luminex to post earnings of $0.13 per share for the quarter.
Luminex (NASDAQ LMNX) opened at $20.13 on Monday. The stock has a market cap of $886.81, a P/E ratio of 30.50, a P/E/G ratio of 1.92 and a beta of 0.13. Luminex has a 12-month low of $17.68 and a 12-month high of $22.42.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Thursday, March 22nd. Luminex’s dividend payout ratio is 36.36%.
In other Luminex news, Director G Walter Loewenbaum II sold 10,503 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $20.61, for a total transaction of $216,466.83. Following the sale, the director now directly owns 564,217 shares of the company’s stock, valued at approximately $11,628,512.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 131,698 shares of company stock worth $2,761,201 over the last three months. Insiders own 6.90% of the company’s stock.
A number of equities analysts recently issued reports on the stock. TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a research report on Wednesday, November 1st. BidaskClub upgraded shares of Luminex from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 10th. Jefferies Group reiterated a “hold” rating and set a $21.00 price objective on shares of Luminex in a research report on Friday, October 20th. Finally, BTIG Research initiated coverage on shares of Luminex in a research report on Friday, January 5th. They set a “buy” rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $21.50.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/05/luminex-lmnx-scheduled-to-post-earnings-on-monday.html.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.